10 March 2014, 2:40 pm
(Kaletra) or 3TC (lamivudine, Epivir) proved equally protective as infant prophylaxis
against HIV infection during 12 months of breastfeeding, Dr Chipepo Kankasa,
presenting on behalf of the ANRS 12174 trial, told participants at the 21st Conference on Retroviruses
and Opportunistic Infections (CROI) last week in Boston.
were equally well tolerated with similar safety
10 March 2014, 12:30 pm
number of studies at last week’s Conference on Retroviruses and Opportunistic Infections (CROI) examined whether people with
HIV had an elevated risk of heart attack and other manifestations of cardiovascular
disease. They came to different conclusions about whether having HIV is in
itself a risk factor for cardiovascular disease (CVD).
10 March 2014, 7:00 am
The Conference on Retroviruses and Opportunistic Infections (CROI) this year heard a number of presentations on phylogenetic analysis – the use of genetic fingerprinting of HIV to trace patterns of transmission and prioritise groups for targeting prevention.If
we take a sample of the genetic make-up of the virus of everyone diagnosed
8 March 2014, 10:00 am
oral combination therapy of two antiretroviral drugs, the non-nucleoside
rilpivirine (Edurant, also in Eviplera/Complera) and the new integrase
inhibitor GSK1265744 (744), was at least as effective as a standard nucleosides-plus-efavirenz
triple combination in keeping viral load undetectable in people taking it, the 21st Conference on Retroviruses and Opportunistic Infections (CROI) heard on Wednesday.
7 March 2014, 12:40 pm
Genetically modified CD4 T-cells lacking CCR5 co-receptors reach high
levels in the body and are resistant to HIV infection, potentially enabling
people to maintain a low viral load while off antiretroviral therapy (ART),
according to the latest reports from studies evaluating Sangamo Biosciences'
zinc finger technology.
Pre-treating patients with the cancer chemotherapy drug cyclophosphamide